Список литературы

1. Арутюнов Г. П. Патофизиологические процессы в почках у больных ХСН. Журнал «Сердечная Недостаточность». 2008; 9(5): 234 - 240.

2. Арутюнов Г.П., Оганезова Л.Г. Экспресс-метод диагностики поражения тубулоинтерстициальной ткани почек при ХСН.

3. Арутюнов Г.П., Оганезова Л.Г., Соколова А.В. Центры здоровья: возможности и перспективы раннего выявления хронической сердечной недостаточности и поражения почек у больных с артериальной гипертензией. Журнал "Клиническая Нефрология". 2012;1: 10 - 16.

4. Арутюнов Г.П., Соколова А.В., Оганезова Л.Г. Экспериментальные модели поражения тубулоинтерстициальной ткани почек: клиническое значение. Журнал Клиническая нефрология. 2011; 2: 75 - 78.

5. Бритов А.Н., Циб А.Ф., Оганов Р.Г. и др. Противоречия и пути решения федеральных целевых программ профилактики дефицита йода и артериальной гипертонии. В кн.: Медико-социальные аспекты состояния здоровья и среды обитания населения, проживающего в йоддефицитных регионах России и стран СНГ. Тверь. 2004: 81-7.

6. Гайтон А. К., Холл Д.Э. Медицинская физиология. Издательство: Логосфера. Пер. с англ. 2008 г.

7. Карпов Ю.А. Индапамид в моно- и комбинированной терапии артериальной гипертонии. Consilium Medicum. Справочник поликлинического врача. 2010; 6:17-19.

8. Клар С. Почки и гомеостаз в норме и при патологии. М: Медицина; 1987.

9. Кушаковский М.С. Гипертоническая болезнь. С-Пб.: СОТИС, 1995.

10. Оганезова Л.Г. Экспресс-метод диагностики поражения тубулоинтерстициальной ткани почек при ХСН. ЖСН. 2011; 12; 1(63): 47 - 49.

11. Преображенский Д. В., Сидоренко Б. А., Маренич А. В. и соавт. Диуретики в лечении артериальной гипертензии. Сonsilium-medicum. Consilium Provisorum. 2002; 2 (1): 22 - 24.

12. Резник Е. В., Гендлин Г. Е., Сторожаков Г. И. Дисфункция почек у больных хронической сердечной недостаточностью: патогенез, диагностика, лечение.

13. Фетисова Н. В., Лукевич Б. Г. Прессорный натрийурез. Нефрология. 2002; 6 (2): 35-8.

14. Чазова И.Е. Национальные рекомендации по диагностике и лечению метаболического синдрома. Журнал кардиоваскулярная терапия и профилактика. 2007; 6(6).

15. Чазова И.Е. Проблема лечения артериальной гипертонии в России. Consilium Medicum. Справочник поликлинического врача. 2007;12: 22 - 23.

16. Шейман Д.А. Патофизиология почки. Пер. с англ -2-е издание. - М. - СПб.: «Издательство БИНОМ» - «Невский Диалект», 1999г.

17. Шмидт Р., Тевса Г. Физиология человека: В 3-х томах. Т3. Пер. с англ. - 3-е изд. - М.: Мир, 2005: 788 - 798.

18. Agabiti-Rosei E., Mancia G., O'Rourke M.F. et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007; 50: 154-160.

19. Ahimastos A.A., Natoli A.K., Lawler A. et al. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture . Hypertension. 2005;45:1194-1199.

20. Alfie M.E., Yang X.P., Hess F. et al. Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem Biophys Res Commun1996; 224: 625-630.

21. Assessment of arterial stiffness in clinical practice. QJM. 2002; 95 (2): 67-74.

22. Bagrov A.Y., Lakatta E.G. The dietary sodium-blood pressure plot “stiffens”. Hypertension. 2004; 44: 22-24.

23. Barba G., Cappuccio F.P., Russo L. et al. Renal function and blood pressure response to dietary salt restriction in normotensive men. Hypertension. 1996; 27: 1160-1164.

24. Barbanoj M.J., Ballester M.R., Antonijoan R.M. et al. A bioavailability/bioequivalence and pharmacokinetic study of two oral doses of torasemide (5 and 10 mg): prolonged-release versus the conventional formulation.ClinExpPharmacol Physiol. 2009;36(5-6):469-77.

25. Barbanoj M.J., Ballester M.R., Antonijoan R.M. et al. Comparison of repeated-dose pharmacokinetics of prolonged-release and immediate-release torasemide formulations in healthy young volunteers.FundamClinPharmacol.

26. Barton M., Vos I., Shaw S. et al. Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis. JASN. 2000; 11: 835-846.

27. Bates J.M., Raffi H.M., Prasadan K. et al. Tamm-Horsfall protein knockout mice are more prone to urinary tract infection: rapid communication. Kidney Int. 2004; 65(3): 791-797.

28. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther. 1993;7 (1):63-8.

29. Ben-Dov I. Z., Bursztyn M. Can Salt Sensitivity of Blood Pressure Be Assessed Without Changing Salt Diet? Hypertension. 2011; 57: 156-157.

30. Bevan J.A. Flow regulation of vascular tone. Its sensitivity to changes in sodium and calcium. Hypertension. 1993;22:273-281.

31. Binder J., Bailey K.R., Squires R.W. et al. Aortic augmentation index is inversely associated with cardiorespiratory fitness in men without known coronary heart disease. Am J Hypertens. 2006;19(10):1019-24.

32. Blacher J., Amah G., Girerd X. et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens. 1997; 10: 1326-1334.

33. Blacher J., Asmar R., Djane S. et al. Aortic Pulse Wave Velocity as a Marker of Cardiovascular Risk in Hypertensive Patients Hypertension. 1999;33:1111- 1117.

34. Blacher J., Guerin A.P., Pannier B. et al. Impact of Aortic Stiffness on Survival in End-Stage Renal Disease Circulation. 1999;99:2434-2439.

35. Bochud M., Staessen J.A., Maillard M. et al. Ethnic differences in proximal and distal tubular sodium reabsorption are heritable in black and white populations. J Hypertens 2009; 27:606-612.

36. Boutouyrie P., Bussy C., Lacolley P. et al. Association between local pulse pressure, mean blood pressure and large artery remodeling. Circulation.

37. Burnett J.C., Costello-Boerrigter L., Boerrigter G. Alterations in the Kidney in Heart Failure: The Cardiorenal Axis in the Regulation of Sodium Homeostasis, in Heart Failure, Mann DL, Editor. 2004: Philadelphia. 279-289.

38. Campese V.M. Salt sensitivity in hypertension. Renal and cardiovascular implications . Hypertension 1994 ; 23 : 531 - 550.

39. Castiglioni P., Parati G., Brambilla L. et al. Detecting Sodium- Sensitivity in Hypertensive Patients. Information From 24-Hour Ambulatory Blood Pressure Monitoring. Hypertension. 2011; 57: 180-185

40. Chae C.U., Pfeffer M.A., Glynn R.J. et al. Increased pulse pressure and risk of heart failure in the elderly. JAMA. 1999;281:934-639.

41. Chang S.S., Grunder S., Hanukoglu A. et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet. 1996;12(3):248-53.

42. Charlton K.E., Steyn K., Levitt N.S. et al. Development and validation of a short questionnaire to assess sodium intake. Public Health Nutrition. 2008; 11(01): 83 - 94.

43. Chen J. Epidemiology of Hypertension and Chronic Kidney Disease in China. Curr Opin Nephrol Hypertens. 2010; 19(3): 278-282.

44. Chiolero A., Maillard M., Nussberger J. et al. Proximal sodium reabsorption: an independent determinant of blood pressure response to salt. Hypertension. 2000; 36: 631-637.

45. Chiolero A., Wurzner G., Burnier M. Renal determinants of the salt sensitivity of blood pressure. Nephrol Dial Transplant. 2001;16:452-458.

46. Chirinos J. A., Zambrano J. P., Chakko S. et al. Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. Hypertension. 2005; 45(5): 980-985.

47. Chirinos J.A., Townsend R. Sodium, potassium, and target organ damage: a case for central hemodynamics. Hypertension. 2010;56 (4):578-580.

48. Cook N.R., Cutler J.A., Obarzanek E. et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP).

49. Cushman W., Materson B., Williams D. et al. Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial. Hypertension. 2001; 38: 953-957.

50. De la Sierra A., Lluch M.M., Coca A. et al. Assessment of salt sensitivity in essential hypertension by 24-h ambulatory blood pressure monitoring. Am J Hypertens. 1995;8 (10): 970-977.

51. Deague J.A., Wilson C.M., Grigg L.E. et al. Physiological relationships between central vascular haemodynamics and left ventricular structure. Clin Sci. 2001; 101:79-85.

52. Deetjen P., Kramer K. Die Abhangigkeit des O2 - Verbrauches der Niere von der Na - Ruckresorption. Pflugers Arch., Europ. J. Physiol. 1961; 273: 636 - 650.

53. Denton D., Weisinger R., Mundy N.I. et al. The effect of increased salt intake on blood pressure of chimpanzees. Nat Med. 1995; 1: 1009-1016.

54. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values. Eur Heart J.2010;31 (19): 2338-2350.

55. Duffield J.S., Grafals M., Portilla D. MicroRNAs are potential therapeutic targets in fibrosing kidney disease: lessons from animal models. Drug Discovery Today: Disease Models. 2012.

56. Dunn C.J., Fitton A., Borgden R. Torasemide: an update of its pharmacological properties and therapeutic efficacy. Drugs. 1995; 49: 121-142.

57. Dussol B., Moussi-France J., Morange S. et al. A Pilot Study Comparing Furosemide and Hydrochlorothiazide in Patients With Hypertension and Stage 4 or 5 Chronic Kidney Disease. The Journal of Clinical Hypertension. 2012;14(1): 32-37.

58. Dzau V.J. Significance of the vascular renin-angiotensin pathway. Hypertension. 1986; 8: 553-559.

59. Eknoyan G. Chronic tubulointerstitial nephropathies. In Diseases of the Kidney, edn 6. Edited by Schrier RW, Gottschalk CW. Boston: Little Brown; 1997:1983-2015.

60. Ellison D.H., Wilcox C.S. Diuretics. In: Brenner B.M (ed).

61. Elzinga L.W., Rosen S, Bennett W.M. Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: role of sodium intake. J Am Soc Nephrol. 1993;4(2):214-21.

62. Epstein M., Hollenberg N.K. Age as a determinant of renal sodium conservation in normal man. J Lab Clin Med 1976;87:411-417.

63. Feig D.I., Madero M., Jalal D. I. et al. Uric Acid and the Origins of Hypertension. The Journal of Pediatrics. 2013; 162(5): 896-902.

64. Ferri C., Bellini C., Carlomagno A. et al. Urinary kallikrein and salt­sensitivity in essential hypertensive males. Kidney Int. 1994; 46: 780-788.

65. Forte J.G, Miguel J.M., Miguel M.J. et al. Salt and blood pressure: a community trial. J Hum Hypertens 1989;3: 179-84.

66. Friedel H.A., Buckley M.M. Torasemide. A review of its pharmacological properties and therapeutic potential Drugs. 1991;41(1):81-103.

67. Fuenmayor N., Moreira E., Cubeddu L.X. Salt sensitivity is associated with insulin resistance in essential hypertension. Am J Hypertens. 1998; 11, 4 (1): 397-402.

68. Fujiwara N., Osanai T., Kamada T. et al. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation. 2000; 101: 856-861.

69. Fukuda M., Kimura G. Salt Sensitivity and Nondippers in Chronic Kidney Disease. Current Hypertension Reports. 2012; 14(5): 382-387.

70. Gariepy C.E., Ohuchi T., Williams S.C. et al. Salt-sensitive hypertension in endothelin-B receptor deficienet rats. J Clin Invest. 2000; 105: 925­933.

71. Gates P.E., Tanaka H., Hiatt W.R. et al. Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. Hypertension. 2004; 44: 35-41.

72. Geleijnse J.M. Sodium, potassium, and blood pressure. Studies in the young and the old. PhD dissertation. Rotterdam, Netherlands: Erasmus University, 1996: 21-31.

73. Glasser S.P., Arnett D.K., McVeigh G.E. et al. Vascular compliance and cardiovascular disease: a risk factor or marker? Am J Hypertens. 1997; 10: 1175­1189.

74. Gnanaraj J.F., von Haehling S., Anker S.D. et al. The relevance of congestionin the cardio-renal syndrome.Kidney International. 2013; 83(3): 384-391.

75. Gomez I.G., Grafals M., Portilla D. et al. MicroRNAs as potential therapeutic targets in kidney disease. Journal of the Formosan Medical Association. 2013; 112(5):237-43.

76. Gropper S., Albet C., Guglietta A. et al. Single-dose, randomized, cross-over bioavailability pilot clinical trial of torasemide immediate release compared

to a new prolonged release formulation of torasemide. Basic Clin Pharmacol Toxicol 2006; 99(1): 48.

77. Gu J.W., Tian N., Shparago M. et. al. Renal NF-κB activation and TNF-α upregulation correlate with salt-sensitive hypertension in Dahl salt-sensitive rats. 2006; 291(6):1817-24.

78. Guyton A.C. Physiologic regulation of arterial pressure. Am. J. Cardiol. 1961; 8: 401-7.

79. Guyton A.C., Coleman T.G. Quantitative analysis of the pathophysiology of hypertension. J. Am. Soc. Nephrol. 1999; 10:2248-58.

80. Guyton A.C., Coleman T.G., Cowley A.W. et al. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med. 1972;52:584-594.

81. Hall J.E. Hyperinsulinemia: a link between obesity and hypertension? Kidney Int. 1993; 43: 1402-1417.

82. He J., Gu D., Chen J. et al. GenSalt Collaborative Research Group. Gender difference in blood pressure responses to dietary sodium intervention in the GenSalt study. J Hypertens. 2009;27(1):48-54.

83. Heidland A., Gerabek W., Sebekova K. Franz Volhard and Theodor Fahr: achievements and controversies in their research in renal disease and hypertension. J Hum Hypertens. 2001;15(1):5-16.

84. Henkin R.J., Gill L.P., Bartter F.C. Study in taste thresholds in normal man — patient with adrenal cortical insufficiency, the role of adrenal cortical steroids and of serum sodium concentration. J. Clin.Invest. 1963; 42: 727-735.

85. Hofman A., Hazebroek A., Valkenburg H.A. A randomized trial of sodium intake and blood pressure in newborn infants. JAMA 1983;250:370-3.

86. Jaffe D., Sutherland L.E., Barker D.M. et al. Effects of chronic excess salt ingestion: morphologic findings in kidneys of rats with differing genetic susceptibilities to hypertension. Arch Pathol. 1970;90:1-16.

87. Jan R.A., Shah S., Saleem S.M. et al. Sodium and Potassium Excretion in Normotensive and Hypertensive Population in Kashmir. JAPI. 2006; 54: 22 - 25.

88. Jankowski P., Kawecka-Jaszcz K., Czarnecka D. et al. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. Hypertension. 2008; 51 (4): 848-855.

89. Jo C.H., Kim S., Park J.S. et al. Effects of dietary salt restriction on puromycin aminonucleoside nephrosis: preliminary data. Electrolyte Blood Press. 2011;9(2):55-62.

90. Johnson R.J., Gordon K.L., Giachelli C. et al. Tubulointerstitial injury and loss of nitric oxide synthases parallel the development of hypertension in the Dahl-SS rat. J Hypertens. 2000;18:1497-1505.

91. Johnson R.J., Gordon K.L., Suga S. et al. Renal injury and salt­sensitive hypertension after exposure to catecholamines. Hypertension. 1999; 34: 151­159.

92. Johnson R.J., Herrera-Acosta J., Schreiner G.F. et al. Subtle Acquired Renal Injury as a Mechanism of Salt-Sensitive Hypertension. N Engl J Med. 2002; 346:913-923.

93. Johnson R.J., Schreiner G. Hypothesis: is essential hypertension an acquired tubulointerstitial renal disease? Kidney Int.1997; 52: 1169-1179.

94. Kaplan N.M., Carnegie A., Raskin P. et al. Potassium supplementation in hypertensive patients with diuretic-induced hypokalemia. N Engl J Med. 1985;312:746-749.

95. Karras A., Haymann J.P., Bozec E. et al. Large Artery Stiffening and Remodeling Are Independently Associated With All-Cause Mortality and Cardiovascular Events in Chronic Kidney Disease. Hypertension.2012; 60: 1451-1457.

96. Khawaja Z., Wilcox C. S. Role of the Kidneys in Resistant Hypertension. Int J Hypertens. 2011; 2011:143471.

97. Kimura G., Brenner B.M. A method for distinguishing salt­sensitive from non-salt-sensitive forms of human and experimental hypertension. Curr Opin Nephrol Hypertens.1993; 2: 341-349.

98. Klag M.J. Whelton P.K., Randall B.L. et al. Blood pressure and end­stage renal disease in men. N Engl J Med. 1996; 334: 13 - 18.

99. Kobori H., Nangaku M., Navar L. G. et al. The intrarenal renin­angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 2007; 59(3):251-287.

100. Kohno M., Yasunari K., Murakawa K. et al. Effects of high sodium and low sodium intake on circulating atrial natriuretic peptides in salt-sensitive patients with systemic hypertension. Am J Cardiol. 1987; 59: 1212-12.

101. Kottgen A., Hwang S.-J., Larson M.G. et al. Uromodulin Levels Associate with a Common UMOD Variant and Risk for Incident CKD. JASN.2010; 21 (2): 337-344.

102. Kullo I.J., Seward J.B., Bailey K.R. et al. C-reactive protein is related to arterial wave reflection and stiffness in asymptomatic subjects from the community . Am J Hypertens . 2005;18:1123-1129.

103. Lacolley P., Labat C., Pujol A. et al. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation. 2002; 106: 2848-2853.

104. Lang F. Stiff endothelial cell syndrome in vascular inflammation and mineralocorticoid excess. Hypertension. 2011; 57:146-147.

105. Langenhoven M., Kruger M., Gouws E. et al. MRC Food Composition Tables, 3rd ed. Parow: Medical Research Council. 1991.

106. Laragh J.H. The renin system and four lines of hypertension research. Hypertension.1992; 20: 267-279.

107. Laurent S., Boutouyrie P., Asmar R. et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236-1241.

108. Lee S., Solow-Cordero D.E., Kessler E. et al. Transforming growth factor-beta regulation of bone morphogenetic protein-1/procollagen C- proteinase and related proteins in fibrogenic cells and keratinocytes. J Biol Chem 1997; 272: 19059-19066.

109. Lehmann E.D., Gosling R.G., Sonksen P.H. Arterial wall compliance in diabetes. Diabet Med. 1992;9:114-119.

110. Levy B.I., Poitevin P., Duriez M. et al. Sodium, survival, and the mechanical properties of the carotid artery in stroke-prone hypertensive rats. J Hypertens. 1997; 15: 251-258.

111. Limas C., Westrum B., Limas C.J. et al. Effect of salt on the vascular lesions of spontaneously hypertensive rats. Hypertension. 1980; 2: 477-489.

112. Liu Y.P., Thijs L., Kuznetsova T. et al. Central Systolic Augmentation Indexes and Urinary Sodium in a White Population. Am J Hypertens. 2013;26 (1): 95-103.

113. Lombardi D., Gordon K.L., Polinsky P. et al. Salt-sensitive hypertension develops after short-term exposure to angiotensin II. Hypertension. 1999; 33: 1013-1019.

114. London G.M., Blacher J., Pannier B. et al. Arterial wave reflections and survival in end-stage renal failure . Hypertension . 2001;38:434-438.

115. Loon N.R., Wilcox C.S., Unwin R.J. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney International. 1989;36(4):682-689.

116. Lopez B., Gonzalez A., Beaumont J. et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 859-867.

117. Lopez B., Gonzalez A., Hermida N. et al. Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney International. .2008;74: 19-23.

118. Lopez B., Querejeta R., Gonzalez A. et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43: 2028-2035.

119. Luft F.C, Grim C.E., Fineberg N., Weinberger M.C. Effects of volume expansion and contraction in normotensive whites, blacks, and subjects of different ages. Circulation1979;59:643-650.

120. MacGregor G, de Wardenerb He. Salt, blood pressure and health. Int. J. Epidemiol. 2002;31 (2): 320-327.

121. Magri P., Rao M.A., Cangianiello S. et al. Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin II antagonism. Circulation. 1998;98 (25):2849-2854.

122. Mahmud A., Feely J. Spurious systolic hypertension of youth: fit young men with elastic arteries . Am J Hypertens. 2003;16:229-232.

123. Mamenko M., Zaika O., Ilatovskaya D.V. et al. Angiotensin II Increases Activity of the Epithelial Na+ Channel (ENaC) in Distal Nephron Additively to Aldosterone. J Biol Chem. 2012; 2, 287(1): 660-671.

124. Mattace-Raso F., Hofman A., Verwoert G.C. et al. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’ Eur Heart J. 2010; 31 (19): 2338­2350

125. McEniery C.M., Yasmin, Hall I.R. et al. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo- Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol 2005;46:1753-1760.

126. Mervaala E., Dehmel B., Gross V. et al. Angiotensin-Converting Enzyme Inhibition and AT1 Receptor Blockade Modify the Pressure-Natriuresis Relationship by Additive Mechanisms in Rats with Human Renin and Angiotensinogen Genes. ASN. 1999; 10 (8): 1669-1680.

127. Midgley J.P., Matthew A.G., Greenwood C.M. et al. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA. 1996;275:1590-1597.

128. Mohanlal V., Parsa A., Weir M.R. Role of dietary therapies in the prevention and treatment of hypertension. Nature Reviews Nephrology. 2012; 15,8(7):413-22.

129. Morimoto A., Uzu T., Fujii T. et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet.1997; 350: 1734­1737.

130. Munkhaugen J., Lydersen S., Wider ne T.E. et al. Prehypertension, obesity, and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway. Am. J. Kidney Dis. 2009; 54(4): 638-646.

131. Mutig K., Kahl T., Saritas T. et al. Activation of the Bumetanide- sensitive Na+,K+,2Cl- Cotransporter (NKCC2) Is Facilitated by Tamm-Horsfall Protein in a Chloride-sensitive Manner. TheJournalofBiologicalChemistry. 2011; 286(34):30200-10.

132. National Research Council. Committee on Diet and Health. Food and Nutrition Board. Commission on Life Sciences. Diet and health: implications for reducing chronic disease risk. Washington, DC: National Academy Press. 1989.

133. Nichols W.W., O’Rourke M.F.; Arnold E. McDonald’s Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles. 3rd ed. London, UK: Arnold; 1990: 77-142, 216-269, 283-359, 398-437.

134. Nichols W.W., O'Rourke M.F. McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles . 5th ed.. London, England: Hodder Arnold; 2005.

135. Nilsson P.M., Boutouyrie P., Laurent S. Vascular Aging. A Tale of EVA and ADAM in Cardiovascular Risk Assessment and Prevention. Hypertension. 2009; 54: 3-10.

136. Nilsson P.M., Lurbe E., Laurent S. The early life origins of vascular ageing and cardiovascular risk: the EVA syndrome [review]. J Hypertens. 2008; 26(6):1049-57.

137. Nurnberger J., Keflioglu-Scheiber A., Opazo Saez A.M.

et al. Augmentation index is associated with cardiovascular risk . J Hypertens. 2002;20 (12):2407-2414.

138. O’Rourke M.F., Staessen J.A., Vlachopoulos C. et al. Clinical Applications of Arterial Stiffness; Definitions and Reference Values. Am J Hypertens. 2002; 15: 426-444.

139. O’Shaughnessy K.M., Karet F.E. Salt handling and hypertension. J Clin Invest. 2004; 113: 1075-1081.

140. Oberleithner H. A physiological concept unmasking vascular salt sensitivity in man. European Journal of Physiology. 2012; 287-293.

141. Oberleithner H. Two barriers for sodium in vascular endothelium? Ann Med. 2012; 44(1): 143-8.

142. Oberleithner H., Peters W., Kusche-Vihrog K. et al. Salt overload damages the glycocalyx sodium barrier of vascular endothelium. Pflugers Arch. 2011; 462:519-528.

143. Oberleithner H., Riethmuller C., Schillers H. et al. Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci USA. 2007;104:16281-16286.

144. Oliver W.J, Cohen E.L, Neel J.V. Blood pressure, sodium intake and sodium related hormones in Yanomamo Indians, a ‘no-salt’ culture.Circulation.1975;52:146-51.

145. O'Rourke M., Vlachopoulos C., Graham R.M. Spurious systolic hypertension in youth. Vasc Med. 2000; 5:141-5.

146. O'Rourke M.F., Seward J.B. Central Arterial Pressure and Arterial Pressure Pulse: New Views Entering the Second Century After Korotkov. Mayo Clinic Proceedings. 2006;81(8): 1057-1068.

147. Page L.B. Damon A., Moellering R.C. Antecedents of cardiovascular disease in six Solomon Islands societies. Circulation 1974; 49:1132-46.

155!

148. Park J.B., Schiffrin E.L. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension. 2001; 37: 1444-1449.

149. Park S., Park J..B, Lakatta E.G. Association of central hemodynamics with estimated 24-h urinary sodium in patients with hypertension. J Hypertens. 2011; 29: 1502-9.

150. Partovian C., Benetos A., Pommies J.P. et al. Effects of a chronic high-salt diet on large artery structure: role of endogenous bradykinin. Am J Physiol. 1998;274: 1423-1428.

151. Pauca A.L., Kon N.D., O'Rourke M.F. The second peak of the radial artery pressure wave represents aortic systolic pressure in hypertensive and elderly patients . Br J Anaesth. 2004;92:651-657.

152. Pauca A.L., Wallenhaupt S.T., Kon N.D. et al. Does radial artery pressure accurately reflect aortic pressure? Chest. 1992; 102:1193-8.

153. Paul M., Mehr A.P., Kreutz R. Physiology of localrenin-angiotensin systems. Physiol Rev. 2006;86: 747-803.

154. Peixoto A.J., Orias M., Desir G.V. Does Kidney Disease Cause Hypertension?. Current Hypertension Reports. 2013; 15(2): 89-94.

155. Pradervand S., Wang Q., Burnier M. et al. A mouse model for Liddle's syndrome. J Am Soc Nephrol. 1999;10(12):2527-33.

156. Preobrazhenski D.V., Nekrasova N.I., Khoseva E.N. at. el. Torasemide is the effective loop diuretic for long-term therapy of arterial hypertension. Kardiologiia. 2011;51(4):67-73.

157. Pries A.R., Secomb T.W., Gaehtgens P. The endothelial surface layer. Pflugers Arch. 2000;440:653-666.

158. Redelinghuys M., Norton G.R. Scott L. et al. Relationship between urinary salt excretion and pulse pressure and central aortic hemodynamics independent of steady state pressure in the general population. Hypertension. 2010 ; 56 : 584 -590.

159. Reyes A.J. Effects of diuretics on renal excretory function, Eur Heart J. 1992;13:15-21.

160. Ritz E. Salt and hypertension. Nephrology. 2010; 15: 49­52.

161. Roca-Cusachs A., Aracil-Vilar J., Calvo-Gomez C. et al. Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release. Cardiovasc Ther. 2008; 26: 91-100

162. Rocchini A.P, Key J., Bondie D. et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989; 321: 580-585.

163. Rodriguez-Iturbe B, Johnson RJ. The role of renal microvascular disease and interstitial inflammation in salt-sensitive hypertension. Hypertens Res. 2010;33(10):975-80.

164. Rodriguez-Iturbe B., Franco M., Johnson R.J. Impaired pressure natriuresis is associated with interstitial inflammation in salt-sensitive hypertension. Nephrol Hypertens. 2013;22(1):37-44.

165. Rodriguez-Iturbe B., Vaziri N.D. Salt-sensitive hypertension— update on novel findings. Nephrol. Dial. Transplant. 2007; 22 (4): 992-995.

166. Rodriguez-Iturbe В., Johnson R.J., Herrera-Acosta A.J. Tubulointerstitial damage and progression of renal failure. Kidney Int. 2009; 68 (99): 82-86.

167. Roson M.I., Cavallero S., Della Penna S. et al. Acute sodium overload produces renal tubulointerstitial inflammation in normal rats. Kidney International.2006; 70(8): 1439-1446.

168. Rostand S.G., Gretes J.C., Kirk K.A. et al. Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. Kidney Int. 1979; 16:600­611.

169. Ruilope L.M., van Veldhuisen D.J., Ritz E .et al. Kidney dysfunction: a sensitive predictor of cardiovascular risk. Am J Hypertens. 2001;14 ;6 (2):213-217.

170. Ruilope L.M.,van Veldhuisen D.J., Ritz E. et al. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol. 2001. 38 (7): 1782-7.

171. Sacks F.M., Svetkey L.P., Vollmer W.M. et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001; 344: 3-10.

172. Safar M.E., Thuilliez C., Richard V. et al. Pressure-independent contribution of sodium to large artery structure and function in hypertension. Cardiovasc Res. 2000; 46: 269-276.

173. Scientific Advisory Committee on Nutrition. Salt and Health, The Stationery Office, 2003: 24-27.

174. Shalitin N., Schlesinger H., Levy M.J. et al. Expression of procollagen C-proteinase enhancer in cultured rat heart fibroblasts: evidence for co­regulation with type I collagen. J Cell Biochem. 2003; 90: 397-407.

175. Shin S.J., Lim C.Y., Rhee M.Y. et al. Characteristics of Sodium Sensitivity in Korean Populations. J Korean Med Sci. 2011; 26(8): 1061-1067.

176. Siegel G., Walter A., Kauschmann A. et al. Anionic biopolymers as blood flow sensors. Biosens Bioelectron. 1996; 11:281-294.

177. Simao A.N., Lozovoy M., Dichi I. The uric acid metabolism pathway as a therapeutic target in hyperuricemia related to metabolic syndrome. Expert Opinion on Therapeutic Targets. 2012; 16 (12): 1175-1187.

178. Skrabal F., Herholz H., Neumayr M. et al. Salt sensitivity is linked to enhanced sympathetic responsiveness and enhanced proximal tubular response. Hypertension. 1984; 6: 152-158.

179. Stamler J. The INTERSALT Study: background, methods, findings, and implications. Am J Clin Nutr. 1997;66(5):1297.

180. Sterzel R.B., Luft F.C., Gao Y. et al. Renal disease and the development of hypertension in salt-sensitive Dahl rats. Kidney International. 1988; 33: 1119-1129.

181. Strazzullo P., Galletti F., Barba G. et al. Altered Renal Handling of Sodium in Human Hypertension Short Review of the Evidence. Hypertension. 2003; 41: 1000-1005.

182. Tanaka T., Okamura T., Miura K. et. al. A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen. Journal of Human Hypertension February. 2002; 16(2): 97-103.

183. The Intersalt Study. J Hum Hypertens 1989;3:179-330.

184. Tokimitsu I., Kato H., Wachi H. et al. Elastin synthesis is inhibited by angiotensin II but not by platelet-derived growth factor in arterial smooth muscle cells. Biochim Biophys Acta. 1994; 1207: 68-73.

185. Torffvit O., Melander O., Hulten U.L. Urinary Excretion Rate of Tamm-Horsfall Protein Is Related to Salt Intake in Humans. Nephron Physiol. 2004;97: 31-36.

186. Tozawa M. Iseki K. Iseki C. et al. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension. 2003; 41: 1341 - 1345.

187. Udani S., Lazich I., Bakris G. L. Epidemiology of hypertensive kidney disease. Nature Reviews Nephrology. 2011; 7:11-21.

188. Van Paassen P., de Zeeuw D., Navis G. et al. Does the renin­angiotensin system determine the renal and systemic hemodynamic response to sodium in patients with essential hypertension? Hypertension.1996; 27: 202-208.

189. Van Paassen P.,de Zeeuw D.,de Jong P.E. et al. Renin Inhibition Improves Pressure Natriuresis in Essential Hypertension. JASN. 2000;11(10):1813- 1818.

190. Van Teeffelen J.W., Brands J., Stroes E.S. et al. Endothelial glycocalyx: sweet shield of blood vessels. Trends Cardiovasc Med. 2007; 17:101-105.

191. Vasan R.S., Larson M.G., Leip E.P. et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001; 17;358(9294):1682-6.

192. Veeraveedu P.T., Watanabe K., Ma M. et al. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem Pharmacol. 2008; 75: 649-659.

193. Veeraveedu P.T., Watanabe K., Ma M. et al. Torasemide, a long- acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy. Eur J Pharmacol. 2008; 581: 121-131.

194. Visser F.W., Boonstra A.H., Lely A.T. et al. Renal Response to Angiotensin II is Blunted in Sodium-sensitive Normotensive Men. Am J Hypertens. 2008; 21 (3): 323-328.

195. Volpe M., Magri P., Rao M.A. et al. Intrarenal determinants of sodium retention in mild heart failure: effects of angiotensin-converting enzyme inhibition. Hypertension. 1997;30, 2 (1):168-176.

196. Wada T., Kodaira K., Fujishiro K. et al. Correlation of ultrasound- measured common carotid artery stiffness with pathological findings. Arterioscler Thromb. 1994;14:479-482.

197. Wargo K.A., Banta W.M. A Comprehensive Review of the Loop Diuretics: Should Furosemide Be First Line? Ann Pharmacother. 2009;43(11):1836- 47.

198. Weber T., Auer J., O'Rourke M.F. et al. Increased arterial wave reflections predict severe cardiovascular events in patients undergoing percutaneous coronary interventions . Eur Heart J . 2005;26:2657-2663.

199. Weinbaum S., Tarbell J.M., Damiano E.R. The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng. 2007; 9:121-16.

200. Weinberger M.H, Miller J.Z, Luft F.C. et al. Definitions and characteristics of sodium sensitivity and blood pressure resistance.Hypertension. 1986;8(2): 127 -134.

201. Weinberger M.H. Salt sensitivity of blood pressure in humans. Hypertension. 1996;27,3 (2):481-90.

202. Whelton P.K., Appel L.J., Espeland M.A. et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized

controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA. 1998; 279(11):839-846.

203. Wilkinson I.B., MacCallum H., Flint L. et al. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol. 2000; 525:263-70.

204. Williams B., Lacy P.S., Thom S.M. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation. 2006; 113: 1213-1225.

205. Williams G.H, Hollenberg N.K. Non-modulating hypertension. A subset of sodium-sensitive hypertension. Hypertension1991; 17 [1]: 81-85.

206. Wilson D.K., Sica D.A., Miller S.B. Ambulatory blood pressure nondipping status in salt-sensitive and salt-resistant black adolescents. Am J Hypertens .1999; 12 (2): 159-165.

207. Yo Y., Nagano M., Moriguchi A. et al. Predominance of nocturnal sympathetic nervous activity in salt-sensitive normotensive subjects. Am J Hypertens.1996; 9: 726-731.

208. Zhao Q., Gu D., Hixson J.E et al. Collaborative Research GroupCirc Common Variants in Epithelial Sodium Channel Genes Contribute to Salt-Sensitivity of Blood Pressure: The GenSalt Study Cardiovasc Genet. 2011;1; 4(4): 375-380.

209. Zieman S.J.,Melenovsky V.,Kass D.A. Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness Arterioscler Thromb Vasc Biol.2005;25(5):932-43.

161